U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809789) titled 'Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants' on Sept. 03.
Brief Summary: This study adopts a single-center, open-label, same-subject sequential crossover clinical trial design, aiming to evaluate the effects of oral administration of rifampicin or itraconazole on the pharmacokinetic profiles of vorolanib tablets in healthy trial participants. The study consists of two treatment groups.
The rifampicin group is planned to enroll 18 healthy trial participants. Participants will receive a single oral dose of vorolanib tablets on the morning of Day 1, and continuous oral administration of rifampicin every m...